Podcasts about approvals

Kevin Surace, Chief Executive Officer at TokenCore, opens with the attack path he says is doing the most damage right now. A phishing email carries a PDF and no links, so it clears the filters. The domain is one character off from the real one, the site is pixel perfect because AI built both the page and the message, and the employee approves an auth prompt they were already expecting. The code was real and the approval was real. Kevin Surace points out that auth apps and passkeys run over cellular and Wi-Fi, so the prompt has no way to know the request came from ten thousand miles away. Anything a person can read or hand over can be shared, and by his account an attacker needs about thirty seconds of trust to get it. Passkeys moved the target rather than removing it. Kevin Surace counts 39 separate passkey attacks in the wild within two weeks of Microsoft telling customers to migrate, and points to Michael Grafnetter of SpecterOps, who presented passkey and Entra research at Black Hat. He walks through the FIDO2 counter that WebAuthn treats as optional so shared passkeys can move between devices. What changes with TokenCore in the mix is where the proof sits. Kevin Surace describes signing into Entra in under two seconds, both passwordless and ID-less, over secure Bluetooth, with the device carrying no apps and no screen. Proximity holds it within three feet of the computer being logged into, the credential stays bound to the original domain, and fingerprints stay off the network. Agents raise the same question in a new place. Kevin Surace describes a policy where an agent action above a million-dollar check needs a person to approve it, and notes that another agent, a hacked one, or a bad actor can clear that approval just as easily. A biometric gate is what tells you the CFO was actually in the room, which is a governance answer as much as a security one. For CISOs, identity architects, and risk owners, the question worth asking is what an identity program looks like when the proof of a person becomes the control, and how much residual risk that removes from privileged access, financial approvals, and agent workflows. This is a Brand Briefing. A Brand Briefing is an on-location conversation recorded on site at Black Hat USA 2026, putting a spotlight on the guest and their company and pairing it with the editorial reach of ITSPmagazine. Learn more: https://www.studioc60.com/performance/#briefing GUEST Kevin Surace, Chief Executive Officer at TokenCore LinkedIn: https://www.linkedin.com/in/ksurace/ RESOURCES Black Hat USA 2026 event coverage: https://www.itspmagazine.com/black-hat-usa-2026-cybersecurity-event-coverage-in-las-vegas Learn more about TokenCore: https://www.tokencore.com TokenCore products: https://www.tokencore.com/products Are you interested in telling your story? ▶︎ Full Length Brand Story: https://www.studioc60.com/content-creation#full ▶︎ Brand Spotlight Story: https://www.studioc60.com/content-creation#spotlight ▶︎ Brand Highlight Story: https://www.studioc60.com/content-creation#highlight ▶︎ Get your own Brand Briefing at an upcoming event: https://www.studioc60.com/buy-brand-briefings KEYWORDS Kevin Surace, TokenCore, Sean Martin, brand briefing, brand story, brand marketing, marketing podcast, Black Hat USA 2026, biometric identity, identity assurance, passkey attacks, MFA relay attack, phishing resistant authentication, auth app compromise, FIDO2, WebAuthn, Microsoft Entra, passwordless authentication, agent authorization, privileged access

Public Works and Infrastructure Minister Dean Macpherson says investigations into several building collapses have uncovered unlawful construction, inadequate supervision, missing approvals, and weaknesses in municipal inspection and enforcement. He says the circumstances differed in each case. Seventeen people died and 24 were injured in building collapses between December last year and March this year. Macpherson has released the findings of investigations into the collapses in Verulam in KwaZulu-Natal, Doornkop in Soweto, Ormonde in Johannesburg, and Sea Point in Cape Town. Thato Letsaba reports.

Stephen Grootes speaks to Tony Carnie, Daily Maverick Investigative journalist, about new government data showing that fewer than 4% of environmental authorisation applications in South Africa were refused over the past two years, raising questions about the effectiveness of the EIA process and proposed reforms to make approvals more flexible. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live on Primedia+ weekdays from 18:00 to 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Part 1:We talk with Harvey Kronberg, publisher of the Texas Quorum Report.We discuss the upcoming elections in Texas, particularly what is happening in Tarrant County (Dallas/Fort Worth). Redistricting and reduction in the number of polling places has caused confusion among voters. We also discuss the effect of AI data center construction. Voters are concerned about the effects on power consumption, and on water consumption. Approvals have been halted.Part 2:We talk with Bill Curry and Ryan Cooper.We discuss the pandemic history revision that Republicans seem to have adopted. The attacks on Dr. Fauci have escalated. We also discuss insider trading by government officials.WNHNFM.ORG  productionMusic: "That's how every empire falls,"  John Prine

The Construction Minister believes a picture is clearly being painted of a recovery in the sector. Stats NZ figures show new home approvals rose 19% annually to June – topping 40 thousand for the first time since 2023. More than 18 thousand consents were issued for standalone houses and 22 thousand for townhouses, representing increases of 17% and 21% respectively. Chris Penk told Mike Hosking consents are just the start of a building process, and although people can't live in them, you wouldn't apply for one without the intention to build. LISTEN ABOVE See omnystudio.com/listener for privacy information.

A building material supplier wants to see the consents given to new homes turn into actual work. Stats NZ figures show approvals rose 19% annually to June – topping 40 thousand for the first time since 2023. Infometrics says Auckland and Canterbury continue to dominate, making up 80% of residential growth. Combined Building Supplies Co-operative CEO Carl Taylor told Ryan Bridge it's a positive sign to see houses being snapped up. He says the real measure on recovery will be seeing projects turn into work on site, which is the biggest issue at the moment. LISTEN ABOVE See omnystudio.com/listener for privacy information.

The Government says its Fast-Track Approvals Act is about cutting through red tape to get more projects built sooner. But councils and community groups are increasingly arguing the legislation is allowing large housing developments to leapfrog years of planning work, leaving local governments to figure out how to fund the roads, water and other infrastructure afterwards. Infrastructure and RMA Reform Minister, Chris Bishop spoke to John Campbell.

July 31, 2026 - New York Focus education reporter Melissa Manno explains the debate between education stakeholders over the authorization of new charter schools in the Empire State.

Condominiums and some commercial space are planned.

Catch up on Australia's biggest property stories this week with Craig and his guests, including interstate migration trends, spring market expectations, building approval changes, the First Home Super Saver Scheme and why buyers should look beyond cosmetic renovations. Practical market insights for homeowners, investors and first-home buyers navigating today's changing Australian property market. You can have your say by leaving a voice message ►  https://www.speakpipe.com/realestateradio ► Website: https://aussierealestatepodcast.lovable.app ► Subscribe here to never miss an episode: https://www.podbean.com/user-xyelbri7gupo ► INSTAGRAM: https://www.instagram.com/therealestatepodcast/?hl=en  ► Facebook: https://www.facebook.com/profile.php?id=100070592715418 ► Email:  myrealestatepodcast@gmail.com  The latest real estate news, trends and predictions for Brisbane, Adelaide, Canberra, Gold Coast, Sydney, Melbourne and Perth. Gold Coast Real Estate, Adelaide Property Market, Luxury Real Estate Australia, Property Investment Podcast, Real Estate Trends 2026, Median Price Growth. We include home buying tips, commercial real estate, property market analysis and real estate investment strategies. Including real estate trends, finance and real estate agents and brokers. Plus real estate law and regulations, and real estate development insights. And real estate investing for first home buyers, real estate market reports and real estate negotiation skills. We include Hobart, Darwin, Hervey Bay, the Sunshine Coast, Newcastle, Central Coast, Wollongong, Geelong, Townsville, Cairns, Ballarat, Bendigo, Launceston, Mackay, Rockhampton, Coffs Harbour. #PropertyInvestment #RealEstateInvesting #FirstTimeInvestor #PropertyManagement #RentalYields #CapitalGrowth #RealEstateFinance #InvestorAdvice #PropertyPortfolio #RealEstateStrategies  #sydneyproperty #Melbourneproperty #brisbaneproperty #perthproperty  #adelaideproperty #canberraproperty #PerthRealEstate #hobartproperty  #RealEstate  #RealEstateNews #MortgageTips #PropertyMarket #FinanceAustralia #BrisbaneInvesting   #RealEstateDevelopment #adelaide #PerthRealEstate #FirstHomeBuyer #AustralianProperty #AustralianRealEstate #PropertyMarketUpdate #MortgageAustralia #FinanceTips #HousingAffordability #RealEstateTrends #AussieProperty  #MortgageRates #HomeLoans  #PropertyMarket #MortgageTips #InterestRates  #BrisbaneProperty #QLDRealEstate #PropertyInvestment #AustralianHousingMarket #AdelaideProperty #AdelaideRealEstate #InvestInAdelaide #SouthAustraliaProperty #AustralianRealEstate #HousingTrends#MelbourneHousing #MelbourneInvestment  #MelbourneMarket  #PropertyInvestment #RealEstateTips #WealthBuilding #InvestmentStrategy #HomeBuying #AustralianProperty    

Nosipho Radebe speaks to Aluwani Museisi, Shell Downstream SA Country Chair See omnystudio.com/listener for privacy information.

We talk with Tim Reardon the chief economist from HIA about Australia's latest building approval figures reveal a growing divide between detached houses and apartments. House approvals have reached their highest level since 2021, while apartment approvals continue to decline. We explore what this means for housing supply, affordability, future property prices and where opportunities may emerge for buyers and investors. You can have your say by leaving a voice message ►  https://www.speakpipe.com/realestateradio ► Website: https://aussierealestatepodcast.lovable.app ► Subscribe here to never miss an episode: https://www.podbean.com/user-xyelbri7gupo ► INSTAGRAM: https://www.instagram.com/therealestatepodcast/?hl=en  ► Facebook: https://www.facebook.com/profile.php?id=100070592715418 ► Email:  myrealestatepodcast@gmail.com  The latest real estate news, trends and predictions for Brisbane, Adelaide, Canberra, Gold Coast, Sydney, Melbourne and Perth. Gold Coast Real Estate, Adelaide Property Market, Luxury Real Estate Australia, Property Investment Podcast, Real Estate Trends 2026, Median Price Growth. We include home buying tips, commercial real estate, property market analysis and real estate investment strategies. Including real estate trends, finance and real estate agents and brokers. Plus real estate law and regulations, and real estate development insights. And real estate investing for first home buyers, real estate market reports and real estate negotiation skills. We include Hobart, Darwin, Hervey Bay, the Sunshine Coast, Newcastle, Central Coast, Wollongong, Geelong, Townsville, Cairns, Ballarat, Bendigo, Launceston, Mackay, Rockhampton, Coffs Harbour. #PropertyInvestment #RealEstateInvesting #FirstTimeInvestor #PropertyManagement #RentalYields #CapitalGrowth #RealEstateFinance #InvestorAdvice #PropertyPortfolio #RealEstateStrategies  #sydneyproperty #Melbourneproperty #brisbaneproperty #perthproperty  #adelaideproperty #canberraproperty #PerthRealEstate #hobartproperty  #RealEstate  #RealEstateNews #MortgageTips #PropertyMarket #FinanceAustralia #BrisbaneInvesting   #RealEstateDevelopment #adelaide #PerthRealEstate #FirstHomeBuyer #AustralianProperty #AustralianRealEstate #PropertyMarketUpdate #MortgageAustralia #FinanceTips #HousingAffordability #RealEstateTrends #AussieProperty  #MortgageRates #HomeLoans  #PropertyMarket #MortgageTips #InterestRates  #BrisbaneProperty #QLDRealEstate #PropertyInvestment #AustralianHousingMarket #AdelaideProperty #AdelaideRealEstate #InvestInAdelaide #SouthAustraliaProperty #AustralianRealEstate #HousingTrends#MelbourneHousing #MelbourneInvestment  #MelbourneMarket  #PropertyInvestment #RealEstateTips #WealthBuilding #InvestmentStrategy #HomeBuying #AustralianProperty    

In this episode, we dive into the hidden revenue leaks that occur behind the scenes when customer payments get declined. Matiss Maliks, Head of Sales and Growth at LTVX.ai, shares how brands can recover lost revenue from failed transactions and boost their payment approval rates. He discusses the hidden pitfalls of relying on a single payment processor , why standard payment setups fall short on recoveries , and how using AI helps plug these financial leaks to scale your business predictably.Topics discussed in this episode:  What causes hidden payment leaks.Why soft declines hurt sales.How AI resurrects failed transactions.What normal approval rates look like.How global selling impacts checkout success.What signs reveal payment infrastructure problems.Why standard processors miss revenue recoveries.Why single payment gateways create risk.How fast onboarding takes to launch.What success fees platforms charge merchants.Links & ResourcesWebsite: https://ltvx.ai/LinkedIn: https://www.linkedin.com/company/ltvxai/X/Twitter: https://x.com/ltvxdotaiGet access to more free resources by visiting the show notes at https://tinyurl.com/4x4tffamI'd love your feedback. Tap the the link to send me a text.______________________________________________________LOVE THE SHOW? HERE ARE THE NEXT STEPS!Follow the podcast to get every bonus episode. Tap follow now and don't miss out!   Rate & Review: Help others discover the show by rating the show on Apple Podcasts at https://tinyurl.com/ecb-apple-podcasts   Join our Free Newsletter: https://newsletter.ecommercecoffeebreak.com/   Support The Show On Patreon: https://www.patreon.com/EcommerceCoffeeBreak   Partner with us: https://ecommercecoffeebreak.com/partner-with-us/

“You buy the hiring platform, and then you don't have these AI workflows enabled... here you are three, four years later. You're still not able to do that.”— Nicole MundyEpisode OverviewIn this episode I'm joined by Nicole Mundy, Senior Research Analyst at Talentech Labs — a research and advisory firm that helps its enterprise clients evaluate and procure hiring technology systems.Nicole brings a valuable perspective to the table because she sees the dynamic between vendor and buyer up close and personal. When combined with my experience in this same realm from the science side- our discussion shines light on the reality of what is happening in AI tech adoption for TA.Topics Discussed & Key Insights1. Companies are buying AI hiring tools at scale — and then leaving them switched off.Among the world's top enterprise organizations, Nicole estimates a surprisingly small amount are actually using AI to automatically assess active applicants.Why?Approvals never come - Companies buy the platform intending to enable the AI, “once the right approvals are in place- but years often pass without any change.Pilots underperform - Big companies test these tools and often conclude they can't really use them, or they just didn't work.Lack of solid ROI evidence - Despite the best intentions- most companies do not do the follow up work needed to demonstrate the impact of these tools on the bottom line. Legal ambiguity freezes decisions - With regulations constantly in flux, risk management often takes priority over business needs.2. Validation is misunderstood and absent.What vendors without I/O science guidance call validation isn't what legal compliance actually requires.* Vendors are quick to speak about the validity of their solution and talk endlessly about validating their AI models — running statistical checks that the model predicts consistently and de-biasing its outputs across groups. This is purely empirical work.* But that's IT-style validation. It confirms the system runs as built; it says nothing about whether the tool is fair or job-related* Validation for legal compliance, and sound science, demands a blend of rational and empirical work to document the job-relatedness of any tool used to make employment decisions3. “Skills” are everywhere, and nowhere.Skills-based hiring is the headline everyone wants. The problem is what counts as a skill.* Most platforms apply the “skill” label with no objective framework to define it. A skill ends up being little more than a tag like “Excel” or “communication”* The definitions behind these labels are usually poorly organized and loosely constructed. * There is no connection between the skills a platform claims to measure and any outcome on the job. Without that link, there is nothing for a buyer to trust or defend.* The companies doing skills-based hiring well are not buying one vendor and flipping a switch. They run multi-year programs: define the skills objectively, inventory what the organization has against what it needs, curate tools carefully on the front end, and collect assessment data at multiple points.4. Cheating is a zero-sum game, so let's change the rulesAI-assisted candidate fraud, from AI completing assessments to coaching candidates through interviews, is driving enterprises toward more dynamic evaluation that is harder to game. But chasing detection is largely a losing battle.* Trying to catch and block AI use is whack-a-mole. It's a zero-sum game, and it's frustrating, because the tools keep getting better and the detection never really gets ahead* There's a more useful way to think about it. People are going to use AI on the job, so why not let them use it in the application process in a controlled way? The question stops being “did they use AI” and becomes “how well do they use it”* Most large organizations are still just trying to get visibility on how much cheating is happening and what it looks like, which says how early everyone is on this.* Across the approaches Nicole sees, one thing tends to hold up whether a process is locked down or fully AI-assisted: competency-based follow-up questions that make candidates explain their own reasoning in their own words.Final TakeawayEnterprise isn't slow on AI in hiring because it doesn't understand the technology. It's slow because the tools are bought on vendor claims that were never reviewed against real science, and the danger only becomes clear once the tool is in play. The companies getting it right aren't chasing tools. They're building programs, science first. Held to that bar, many of the tools on the market today wouldn't survive the review, and the ones that would wouldn't be sitting switched off. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit charleshandler.substack.com

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

Have you ever wondered why Capital One's approval decisions feel completely random - approval for some, denial for others, with almost no rhyme or reason?   Capital One has a well-earned reputation for being unpredictable with credit card approvals. When Katie from Katie's Travel Tricks saw the launch of the new Capital One Business Venture card, she decided to move beyond anecdotes and collect real data. She surveyed her audience about their approval and denial experiences, gathered nearly 150 responses, and analyzed the patterns using data to answer the questions everyone has been asking: what actually matters to Capital One?   Katie and I break down what her data revealed about the three strongest approval predictors, why the conventional wisdom about waiting six months between Capital One applications might not be accurate, which metrics matter (credit score, hard inquiries, pre-approval status) and which ones surprisingly don't, and how business structure (sole proprietor versus LLC) impacts your approval chances. We also discuss what role the Capital One Business Venture Card plays in your overall rewards strategy and how to think about it within the larger Capital One ecosystem.   Get full show notes and transcript: https://pointmetofirstclass.com/capital-one-approvals-data       Eager to learn the secrets of award travel so that you can turn your expenses into unforgettable experiences? Join the Points Made Easy course waitlist here: https://pointmetofirstclass.com/pointsmadeeasy  

While most investors have been rattled by the tax overhaul, the biggest risk right now isn't the budget itself, but how lenders are reacting to it, with pre-approvals increasingly unreliable and buyers at risk of being caught mid-deal. On The Smart Property Investment Show, Phil Tarrant speaks with Eva Loisance, principal at Finni Mortgages, about the post-budget lending shake-up and what it means for investors trying to secure finance in an increasingly unpredictable environment. Loisance explains that pre-approvals are no longer a safe assumption, with some lenders already stripping out negative gearing from servicing models while others hold the line pending clearer legislation. She warns the real impact is already hitting borrowing power, with modelling showing some dual-income households could lose close to 30 per cent in lending capacity if servicing rules fully exclude negative gearing benefits. As uncertainty flows through the system, lenders are tightening conditions, reassessing risk, and quietly reshaping what investors can actually borrow – well before any law is finalised. The episode also explores how investors may pivot, including a shift toward new-build stock that retains tax treatment advantages, despite higher costs limiting feasibility for many. Loisance flags potential flow-on effects into the rental market, with investors forced to chase yield more aggressively as tax efficiency is stripped back and holding costs rise. If you like this episode, show your support by rating us or leaving a review on Apple Podcasts and by following Smart Property Investment on social media: Facebook, X (formerly Twitter) and LinkedIn. If you would like to get in touch with our team, email editor@smartpropertyinvestment.com.au for more insights, or hear your voice on the show by recording a question below.

Summary: In this episode of the Ops Experts Club podcast, Aaron Hovivian and Terryn Turner unpack one of the most overlooked areas in business operations: vendor payments, contract management, and approval systems. They dive into the dangers of blindly paying invoices without proper checks and balances, sharing real examples of businesses that were unknowingly exposed to duplicate billing, disorganized contracts, and financial inefficiencies. From contract repositories and approval workflows to task management systems and AI-powered organization, the conversation breaks down practical ways operators can protect growing businesses from costly mistakes. Aaron and Terryn also explore the important role operations leaders play between finance, bookkeeping, HR, and leadership teams. They discuss why visionary entrepreneurs often need structured operational support, how trust and accountability are built within approval systems, and why organized documentation becomes critical as companies scale. Whether you're running a small online business or managing a fast-growing team, this episode offers actionable systems and operational insights to help you tighten up your backend processes and create better financial oversight. To learn more about operational audits, bookkeeping systems, and financial process support, visit Finance.TheCollabTeam.com Minute by Minute 00:00 Welcome to Ops Experts Club 01:20 The Importance of Systems in Online Business 02:16 Managing Contracts and Payments 04:57 Organizing Contracts and Approvals 09:15 Creating a Contract Repository 11:06 Approval Processes in Finance 14:40 Managing HR and Contractor Agreements  

Dive into the latest episode of Pharmacy Friends for a discussion of the FDA Commissioner's National Priority Voucher pilot. While accelerated approvals may improve access to innovative therapies, what could a compressed decision-making window mean for evidence review, affordability assessment and implementation planning? Prime experts Angela Sutton and Bob Greer explore the important roles clinical confidence and operational readiness will play in making solid coverage decisions. Hear what they're most focused on, including:Managing drug spendAssessing coverage strategiesDetermining policy risk00:00 Introduction02:10 What's generating all the questions now?04:35 FDA Hearing05:50 Pro's and con's of accelerated drug approvals11:05 Policy uncertainty and impact to payers11:54 Impact of FDA leadership changes12:24 Meeting the moment15:26 Using data to make better decisions that need to be fast18:39 What we would tell the acting FDA leadership that matters23:15 Closing

#280: Learn how to dramatically improve your odds of getting approved for the credit cards you actually want. Chris breaks down the hidden system every bank uses to evaluate applications, why your credit score matters far less than what's on your report, and the real factors driving denials, from credit-to-income ratios to recent inquiries to each issuer's internal model. He also walks through what to do before you apply, how to sequence applications across issuers, and the right moves to make after a denial. Link to Full Show Notes: https://chrishutchins.com/credit-card-approval-strategy. Partner Deals Quince: Affordable luxury essentials with free shipping + 365 day returns Mercury: Help your business grow with simplified finances Wispr Flow: ⁠Try effortless voice dictation for free Fabric: ⁠Affordable term life insurance for you and your family LMNT: ⁠Free sample pack of my favorite electrolyte drink mix For all the deals, discounts and promo codes from our partners, go to: ⁠chrishutchins.com/deals Resources Mentioned Credit Cards The Atmos™ Rewards Visa Summit Card The Business Platinum Card® from American Express Southwest Rapid Rewards® Plus Credit Card Capital One Venture X Business Capital One Venture X Rewards Credit Card Capital One Spark Cash Plus Tools & Resources Doctor of Credit MyFICO Forums LexisNexis Articles Complete Guide to Credit Card Application Rules by Bank ATH Podcast #221: Deep Dive on Credit Reports, Scores, and Their Real-World Impact #228: Deep Dive on Citi Credit Cards and ThankYou Points (Best 2-Card Combo) #236: Deep Dive on Amex Credit Cards and Membership Rewards Points #242: Deep Dive on Capital One Credit Cards and Miles (+ Why I Love Them) #247:Deep Dive on Bank of America Credit Cards (Up to 5.25% Cash Back) Best Cards Page AMA: Submit A Question Newsletter Leave a review: Apple Podcasts | Spotify Email for questions, hacks, deals, and feedback: podcast@chrishutchins.com Full Show Notes (00:00) Introduction (03:50) Why Chris Lets His Cards Report High Balances (05:06) When Your Credit Score Actually Matters (05:53) Why Business Cards Stay Off Your Credit Report (06:39) What Actually Counts as a Business (10:55) How Your Credit-to-Income Ratio Drives Approvals (14:48) What Your Payment History Reveals (15:08) Why Recent Inquiries Can Sink Your Application (17:44) The Chase 5/24 Rule Explained (18:44) The Hidden Internal Models Banks Use (19:18) Diagnosing a Listener's Surprise 820-Score Denial (24:56) What to Check Before You Hit Submit (25:55) Sequencing Business Card Applications for Approval (28:05) The Best Personal Card Offers Right Now (28:50) Why a Checking Account Can Boost Your Odds (30:10) Using Frozen Credit Bureaus to Your Advantage (32:37) Tag-Teaming Applications With a Partner (33:32) Why Last-Minute Fixes Don't Work (34:32) Using Pre-Qualification Tools to Avoid Hard Pulls (34:49) Cutting Unnecessary Credit to Get Approved (35:27) What Actually Happens After a Denial (40:54) When It Makes Sense to Close a Card (44:26) The Hidden Value of Card-Linked Offers (46:15) Every Major Bank's Application Rules (48:45) The Mindset Shift That Changes Everything Connect with Chris ⁠⁠Newsletter⁠⁠ | ⁠Membership⁠⁠ | ⁠X⁠⁠ | ⁠Instagram⁠⁠ | ⁠LinkedIn⁠⁠ Editor's Note: The content on this page is accurate as of the posting date; however, some of our partner offers may have expired. Opinions expressed here are the author's alone, not those of any bank, credit card issuer, hotel, airline, or other entity. This content has not been reviewed, approved or otherwise endorsed by any of the entities included within the post. Learn more about your ad choices. Visit megaphone.fm/adchoices

Zip Loan supports merchant growth with technology-driven financing solutions that simplify approvals and enhance the customer experience. Zip Loan City: Matthews Address: 624 Matthews-Mint Hill Road Website: https://www.zip-loan.com/ Phone: +1-877-308-0088 Email: info@zip-loan.com

In this episode I discuss bioequivalence testing and how it was developed to support generic drug approvals, but is now a mainstream tool for all of drug development. I discuss the basics of what bioequivalence means, how the studies are designed, and then how to perform the statistical analysis. I end with some examples of how this can be used for both generic drug and innovator drugs to support labeling. Links discussed in the show:FDA Draft Guidance: Statistical Approaches to Establishing Bioequivalence (Dec 2022) – Excellent detail on methods, models, and SAS examples. FDA Guidance: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. Article: “Bioequivalence of generic drugs: a simple explanation for clinicians” (Andrade, 2015) – Great for the 80-125% intuition. R-script with example BE analysis (Be sure to copy this text into a file and name it "BE-example.R" then you can run it on your local R instance.You can connect with Nathan on LinkedIn and send me a message Send Nathan a message Sign up for Nathan's newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

The Tim Conway Jr. Show Hour 1 (5.20) It’s the Wednesday before Memorial Day weekend and people are already starting to get out of town. But many plans have changed because of the wildfires in Simi Valley and Ventura County. Is it air purifier season? And it’s the last Memorial Day to hang out at Primm before the resort closes forever! Are you going to the beach for Memorial Day weekend? If so, for heaven’s sake do not pick Santa Monica, because the area around Santa Monica Pier ranks No. 1 as the dirtiest beach in California. If you live in Rancho Palos Verdes, it’s a nightmare to undergo home renovations because you’re at the mercy of overly restrictive regulations. Approvals are often costly and unnecessary, and many homeowners just give up. And if they draw attention to it, they may face repercussions from the Palos Verdes Home Association & Art Jury. See omnystudio.com/listener for privacy information.

Today – Mansfield’s push to bring Buc-ee’s to the I-71 and Ohio 39 interchange took a major step forward this week, but the project still has a few more approvals ahead.Support the show: https://richlandsource.com/membersSee omnystudio.com/listener for privacy information.

Shannon Joseph, chair of Energy for a Secure Future, says Canada is finally moving from endless debate toward clearer rules and timelines around major energy infrastructure — but warns investor confidence, Indigenous buy-in, and legal risks will ultimately determine whether a new bitumen pipeline actually materializes. She argues Canada's LNG sector offers a roadmap for how oil projects can succeed through regulatory certainty, faster approvals, and Indigenous ownership models.Energy for a Secure Future is a member of The Hub's Corporate & Industry Council.The Hub is Canada's fastest growing independent digital news outlet. Subscribe to The Hub's podcast feed to get all our best content:https://tinyurl.com/3a7zpd7e (Apple)https://tinyurl.com/y8akmfn7 (Spotify)Watch a video version on YouTube: https://www.youtube.com/@TheHubCanadaFollow The Hub on X: https://x.com/thehubcanada?lang=en CREDITS:Elia Gross - Producer and Sound EditorAmal Attar-Guzman - Video Editor Falice Chin - Host Hosted on Acast. See acast.com/privacy for more information.

On this episode of Closed!, Lee Bergstein is joined by Mark Levine, Principal at EBMG LLC, Accredited Property Management LLC, and Apex Management Group—one of New York City's most active property managers, overseeing hundreds of co-op and condominium buildings across the city. Together, they break down one of the most frustrating and opaque parts of NYC real estate: the co-op board application process.From incomplete applications and internal board dynamics to the real reasons deals get delayed or denied, Mark offers a behind-the-scenes look at how these decisions are actually made—and where things most often go wrong. The conversation also dives into the upcoming legislation imposing strict timelines on board approvals, what it means for buyers, sellers, and boards, and whether it will truly fix the system or just create new challenges.Co-op approvals can make or break a deal—and they impact everyone involved. In this episode, Lee and Mark unpack the pain points, the pressure, and the potential reforms shaping the future of NYC real estate transactions.If you love law, real estate, or New York City, then this is an episode for you.To learn more about Mark Levine and his companies, visit: http://www.manageyourbuilding.com/ or ebmg.com. To find out more about Bergstein Flynn Knowlton & Pollina PLLC, visit our website at bfkplaw.com. Hosted on Acast. See acast.com/privacy for more information.To find out more about Bergstein Flynn Knowlton & Pollina PLLC, visit our website at bfkplaw.com. Hosted on Acast. See acast.com/privacy for more information.

John Highley breaks down what it actually looks like inside a PDR shop once the hail hits. This episode is straight shop talk—insurance delays, adjuster issues, storage strategy, approvals, and how to keep jobs moving when everything is backed up and chaotic. If you've worked a storm, you already know… this is where the real game starts.

Conservative energy critic Shannon Stubbs; The Front Bench with Christy Clark, Marco Mendicino, James Moore and Tony Clement; Brian Kingston, President and CEO of the Canadian Vehicle Manufacturers' Association; A live press conference with B.C. Premier David Eby; CTV Ottawa Bureau Chief Graham Richardson.

If your write-up is weak… your paycheck is leaking. Period. In this episode, I'm going straight at one of the most overlooked, but most expensive breakdowns in your service department: the quality of your RO write-up. We're talking about the real impact of vague notes, rushed conversations, and missed questions and how they quietly destroy technician productivity, create comebacks, slow down approvals, and chip away at your income. I break down exactly how to level up your write-up process, what questions actually matter, and how to position yourself as the translator between your customer and your technician. This is one of those "simple but not easy" skills that separates average advisors from top earners. Better notes = faster diagnosis, smoother workflow, stronger trust, and more money in your pocket. If you're ready to clean up the chaos and take control of your lane… this is your play. Dealer Talk with Jen Suzuki Podcast |

Greek golden visa approvals jumped nearly 96% in 2025, and the government just dropped a 31-page circular targeting fake deals fueling the boom. In this video, you'll learn the new fraud rules, the €250,000 option that survives, and why the Airbnb ban is narrower than the headlines suggest.Read the full story here.

The federal government says demand for parent visas will always outstrip Australia's capacity to grant them. With places capped at 8,500, high demand continues to drive long waiting times. Assistant Minister for Citizenship, Customs and Multicultural Affairs Julian Hill says the government has increased the number of visas granted and is open to considering changes. In this podcast, we speak to an Indian Australian Sunita Kalkal who says the long wait is difficult and is urging the government to develop new policies.

Welcome and thanks for tuning in to this mid-week edition of RealAg Radio with your host Shaun Haney, brought to you by FMC Ag Canada! On today’s show, Haney is joined by: Kelvin Heppner of RealAgriculture to discuss the Conservative Private Members' Bill; Bryan O'Hara of FMC Ag Canada for a spotlight interview; USDA Deputy... Read More

Welcome and thanks for tuning in to this mid-week edition of RealAg Radio with your host Shaun Haney, brought to you by FMC Ag Canada! On today’s show, Haney is joined by: Kelvin Heppner of RealAgriculture to discuss the Conservative Private Members' Bill; Bryan O'Hara of FMC Ag Canada for a spotlight interview; USDA Deputy... Read More

WBBM political editor Geoff Buchholz reports on a proposal that could speed up approval for legal video gambling terminals in Chicago bars and restaurants.

WBBM political editor Geoff Buchholz reports on a proposal that could speed up approval for legal video gambling terminals in Chicago bars and restaurants.

WBBM political editor Geoff Buchholz reports on a proposal that could speed up approval for legal video gambling terminals in Chicago bars and restaurants.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the fast-paced changes shaping these sectors, focusing on the latest scientific breakthroughs, regulatory shifts, and industry trends.First off, Denali Therapeutics has achieved a significant milestone with FDA approval for its enzyme replacement therapy targeting Hunter syndrome, a rare genetic disorder. This therapy addresses neurological complications that have been challenging to treat, marking a pivotal moment for the rare disease community. Hunter syndrome is characterized by enzyme deficiencies leading to harmful accumulations in the body. The availability of this treatment not only provides new hope for patients but also underscores the potential of targeted therapies to manage complex neurological symptoms effectively.In oncology, Corcept Therapeutics has secured FDA approval for Lifyorli (relacorilant), designed for platinum-resistant ovarian cancer patients who have already undergone multiple lines of systemic treatment. This approval highlights the critical importance of strategic clinical trial design and persistent regulatory engagement, expanding treatment options for a patient population with limited alternatives.Meanwhile, Ionis Pharmaceuticals made headlines by slashing the annual price of Tryngolza by 93% ahead of its intended label expansion for severe hypertriglyceridemia. This strategic move aims to make the drug more accessible and capture a broader market share while addressing pricing pressures from regulators and patients alike. Such pricing strategies might set new precedents in the industry, particularly for drugs initially developed for rare diseases now targeting more common conditions.The funding landscape presents challenges as biopharma investment has dropped 20% in 2025. Companies are now prioritizing high-impact projects over broader portfolios, reflecting a shift towards focused R&D investments. This cautious climate may accelerate breakthroughs in prioritized areas yet poses risks if diversification is neglected.Regulatory dynamics are also in flux. The departure of Dr. Robert Malone from the CDC's Advisory Committee on Immunization Practices highlights ongoing tensions within vaccine advisory panels. These developments underscore the intricate balance between scientific evidence, public health policy, and stakeholder communication in guiding vaccine-related decisions.Technological advancements continue to reshape operations within life sciences companies. AI-driven platforms are playing a vital role in enhancing Medical-Legal-Regulatory processes by offering adaptable solutions that transcend traditional automation limits. This innovation is crucial for organizations aiming to optimize regulatory compliance while maintaining operational efficiency.In medical devices, Philips' AI-powered cath lab copilot has gained FDA clearance in collaboration with Edwards Lifesciences. This technology assists in transcatheter mitral valve repair—a complex procedure requiring precision and real-time data analysis—illustrating how AI can significantly enhance procedural outcomes and patient safety.Shifting focus to genetic therapies, Beam Therapeutics has shown promising progress with its base editing technology for alpha-1 antitrypsin deficiency (AATD), potentially revolutionizing treatment approaches for genetic disorders. Similarly, Sarepta Therapeutics is advancing RNA-based treatments with positive biomarker data for muscular dystrophies, reinforcing RNA therapies as viable alternatives or complements to traditional gene therapies.However, not all news is positive. Wave Life Sciences faced a setback when its obesity drug candidate showed only a modest reduction in body weight over six months. This highlights the competitive pressures and high expectations within metabolic disoSupport the show

3,172 approvals and nearly US$1B in deposits and property; MM2H's rebound from its disastrous 2021 overhaul is now quantifiable.View the full article here.Subscribe to the IMI Daily newsletter here. 

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it.   https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice.  The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests   XX   Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments.   https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX   The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It's about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott. MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0. MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes. https://www.prnewswire.com/news-releases/minimed-announces-fda-clearance-of-minimed-flex-the-companys-smallest-insulin-pump-featuring-its-first-smartphone-controlled-design-302716864.html   XX Lots of new out of the recent ATTD conference.. some headlines: New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year. -- The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells. -- Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times.   Researchers noted that the body's response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows. -- More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide.   Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years.   Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85. https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026   XX Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it's the world's first fully closed loop commercial launch. CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife's (formerly Ypsomed Diabetes Care's) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device. https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/ XX Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes. The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy. Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027. Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study.   https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/ XX Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to  Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.

Ever wondered why no new 8(a) companies are being approved—and what that means for your government contracting strategy? In this episode, we break down the current 8(a) program freeze and what it means for small businesses trying to break into federal contracting. Despite the slowdown in approvals, opportunities are still flowing—and in some cases, increasing. We dive into how experienced contractors are navigating this challenge, including creative strategies like joint ventures, partnerships, and even transferring ownership of existing 8(a) companies to stay competitive. You'll learn: Why 8(a) approvals have stalled and what the data actually shows How to leverage existing 8(a) companies to access sole-source contracts Why attending industry events and networking is still the fastest path to opportunities If you're serious about winning government contracts, this episode will help you pivot, adapt, and stay ahead—no matter what changes happen in the program. If you want to learn more about the community and to join the webinars go to: https://federalhelpcenter.com/ Website: https://govcongiants.org/ Connect with Encore Funding: http://govcongiants.org/funding

Conrad Black Conrad Black discusses Prime Minister Mark Carney's commitment to defending the Northwest Passage with military investment. He highlights how pipeline project approvals serve as a vital litmus test for maintaining Canadian national unity. Carney's Arctic Defense and the Pipeline Litmus Test (1)1932 COMMONS OTTAWA

The global medical device regulatory environment is complex, often requiring manufacturers to repeat similar submissions and audits across multiple countries. This duplication slows innovation and delays patient access to life-saving technologies.To address this challenge, international regulators are increasingly collaborating through the International Medical Device Regulators Forum (IMDRF).In this podcast episode, Stephanie Grassmann (MedTechXperts) joins us to discuss how the concept of Regulatory Reliance is transforming global medical device approvals.What is IMDRF?The International Medical Device Regulators Forum (IMDRF) is a voluntary group of regulatory authorities working together to harmonize medical device regulations and reduce duplication across global markets.Members include major regulatory bodies such as:• United States (FDA)• European Union• Australia (TGA)• Brazil (ANVISA)• Canada (Health Canada)• China (NMPA)Their mission is to promote efficient regulation while maintaining high standards of safety and performance.Understanding Regulatory RelianceRegulatory reliance allows one authority to give significant weight to the work already performed by another trusted regulator.Instead of repeating full assessments, authorities can leverage existing evaluations, reducing regulatory burden while maintaining confidence in safety and effectiveness.Real-World Success StoriesSeveral regulators are already demonstrating the benefits of reliance mechanisms.Australia – TGAA Class III Mitral Valve Clip reached market access in just 20 working days after the regulator accepted evidence generated overseas.Argentina – ANMATDental instruments known as endodontic barbed broaches were approved in 9 working days using reliance pathways.Brazil – ANVISACompanies holding MDSAP certification may skip immediate on-site audits, saving both time and money during market entry.These examples show how regulatory cooperation can significantly accelerate approvals.The Role of MDSAPThe Medical Device Single Audit Program (MDSAP) allows manufacturers to undergo a single regulatory audit recognized by multiple countries.This program plays a key role in enabling reliance between regulatory authorities and reducing redundant inspections.The European PerspectiveEurope has historically maintained a distinct regulatory framework under EU MDR and IVDR.However, recent proposals—including references to Articles 108a and 108b—suggest increasing collaboration with international frameworks such as IMDRF and MDSAP.While a single global approval system remains a long-term goal, reliance initiatives are already demonstrating that cooperation between regulators can improve efficiency without compromising safety.Looking AheadFor manufacturers and startups, embracing international regulatory frameworks early—such as MDSAP and IMDRF guidance—can significantly improve global market access strategies.As regulatory collaboration grows, the future of medical device approvals may become faster, more harmonized, and more patient-centered.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkStephanie Grassmann Linkedin: https://www.linkedin.com/in/stephaniegrassmann-medtechxperts/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is powered by Podcastics, the easiest platform to create and publish your podcast.

Ryan and I discuss how to use MTRX for to get more approvals for your jobs and earn more Money in your business. Most of you have this tool. It's time to learn how to use it to its max potential! www.dentprosacramento.com  

Patrick Carino shares how he sources ground-up multifamily deals, navigates Northeast development, and built DealNav out of his Excel frustration. The Crexi Podcast connects commercial real estate (CRE) professionals with industry insights built for smart decision-making. In each episode, we explore the latest trends, innovations and opportunities shaping commercial real estate, because we believe knowledge should move at the speed of ambition and every conversation should empower professionals to act with greater clarity and confidence.   In this episode, host Shanti Ryle sits down with Patrick Carino, Vice President of Development at the NRP Group, to discuss the latest trends, insights, and strategies shaping multifamily development across the Northeast. They explore Patrick's unconventional path into real estate — starting with punch lists in high school — through his years at CBRE and into his current role sourcing and executing ground-up developments across New York, New Jersey, Connecticut, and Massachusetts. They also delve into Patrick's strategic approach to cold outreach and job hunting, the nuances of buying land that is subject to approvals, and what macro forces are reshaping deal economics today. Patrick also shares the origin story of DealNav, the map-based CRM he built for himself that accidentally became a product — and why he believes a human touch is still best for finding deals. Guest Introduction: Patrick Carino Starting in Real Estate in High School From Spec Homes to Multifamily Leasing Studying Real Estate at UConn Landing at CBRE's New York Institutional Group Learning the Market Through Deal Volume A Strategic Approach to Job Hunting and Cold Outreach How to Stand Out in Networking Conversations The Role Patrick Built at NRP Group Specialist vs. Generalist Models in Development How NRP's Teams Collaborate Across the Deal Lifecycle Deal Sourcing Criteria: Land, Size, and Approvals Buying Subject to Approvals — and Why It Matters Three Ways Patrick Sources Deals What Can Make or Break the Entitlement Process How Rates, Tariffs, and Regulations Affect the Northeast Market-by-Market: New York, New Jersey, and Massachusetts What Keeps Patrick Up at Night — and What Excites Him Why Passion and Patience Are Essential in Development The Origin Story of DealNav Building a Simple, Map-Based CRM for Deal Tracking How Twitter Led to an Accidental Product Launch DealNav's Roadmap: Custom Fields, Map Features, and Integrations Why DealNav Doesn't Use AI — and Why That's Intentional Rapid Fire: Investment Picks, Worst Advice, and Parting Wisdom For show notes, past guests, and more CRE content, please check out Crexi's blog.Looking to stay ahead in commercial real estate? Visit Crexi to explore properties, analyze markets, and connect with opportunities nationwide. Follow Crexi:https://www.crexi.com/​ https://www.crexi.com/instagram​ https://www.crexi.com/facebook​ https://www.crexi.com/twitter​ https://www.crexi.com/linkedin​ https://www.youtube.com/crexi

Benson officials face a March 6 deadline to answer state investigators as the Attorney General’s office keeps digging into whether the city’s Planning and Zoning Commission followed Arizona’s open meeting rules during key votes on the Aluminum Dynamics permit.Support the show: https://www.myheraldreview.com/site/forms/subscription_services/See omnystudio.com/listener for privacy information.

Alexander Embiricos is the Head of Codex at OpenAI, leading the development of the company's flagship AI coding systems that power automated software generation, debugging and developer workflows. Under his leadership, Codex has become one of the most widely adopted AI developer platforms.  AGENDA: 05:13 Will Coding Be Automated? Why AI Could Create More Engineers, Not Fewer 07:17 Do We Need PMs? The "Undefined" Product Role and When It Matters 08:06 The Real AGI Bottleneck: Human Prompting, Validation, and "Too Much Effort" 13:04 Three Phases of Agents: Coding → Computer Use → Productized Workflows 13:52 Enterprise Reality Check: Security, Permissions, and Safe Agentic Browsing 17:57 Is Inference the New Sales and Marketing?  18:49 What % of Codex Was Written by AI? 21:33 Do OpenAI Use AI for Code Review? 23:31 Is there any stickiness to AI coding tools? 28:22 What Does "Winning" Mean at OpenAI? Mission, Competition, and Moats 32:04 The Future UI: Chat or Voice 34:10 Agent-to-Agent Workflows: Designing for Approvals, Compliance, and Automation 35:39 Do Coding Models Have a Data Moat? 36:50 How does Codex View Data: Will They Build Their Own Mercor and Turing? 37:27 How Does Codex View Consumer: Will They Compete with Lovable? 41:56 Benchmarks vs "Vibes": How People Actually Judge Models 42:43 Cursor's Edge and the Case for Building Your Own Models 47:37 Is SaaS Dead? What Still Defends Value (Humans + Systems of Record) 51:28 Talent Wars and Career Advice for New Engineers in the AI Era 01:01:03 Guardrails, the Fully AI-Managed Stack, and a 10-Year Vision for Everyone      

Guest: Bob Zimmerman. Musk announces SpaceX will prioritize the Moon before Mars; regulatory approvals for Starship launches are pending, while Voyager Space secures a management contract for ISS operations.1906. WELLS. MARTIAN

What does it take to win a competitive retail LOI today?Retail leases are moving fast again, and in East Tennessee, they are moving faster than most people think is possible.Chris Ressa talks with Lindsey Barden, founder of Dark Horse CRE, a tenant-rep-only broker covering Knoxville, Chattanooga, and the Tri-Cities. Her view from the ground is simple: vacancy is extremely low, the best spaces trade off-market, and retailers are routinely battling multiple LOIs for the same box. In the past six months, Lindsey says 80-to-90 percent of her deals have been competitive, forcing brands to show up ready to commit, pay closer to asking, and cut through internal red tape.Landlords are prioritizing certainty and speed, especially in second-generation space. The tenants winning deals are the ones asking for less work and fewer dollars from ownership, tightening timelines, and moving from “perfect protections” to more balanced lease terms.The proof point is a Crunch Fitness anchor lease that went from discovery to signed lease in roughly two weeks. No traditional LOI. Basic terms handled by email. Architects and contractors brought in immediately. Approvals happening across time zones. A two-level layout that required creative planning, not a cookie-cutter prototype. Two motivated parties decided the deal mattered, and executed like it.If you want a takeaway: stop treating leasing like a slow process. Treat it like a race. Speed wins.What You'll HearWhy East Tennessee is one of the tightest retail markets in the country — and what low vacancy really means for tenants trying to expand.What 80 to 90 percent competitive deal flow looks like in practice — multiple LOIs, limited second-generation space, and constant off-market conversations.How landlords are prioritizing certainty over creativity — why minimal TI, faster approvals, and fewer contingencies are winning deals.What retailers must change internally to compete — consolidating corporate review, accelerating decision-making, and committing earlier.How a Crunch Fitness anchor lease went from tour to signed in 14 days — no traditional LOI, creative problem solving on a two-level box, and approvals happening across time zones.Why speed is the ultimate differentiator in today's leasing environment — and how motivated parties can compress timelines dramatically.A thoughtful look at retail saturation vs. market expansion — coffee, chicken, gyms, and how to separate durable concepts from passing trends.The mindset shift required to win in 2026 retail real estate — treat leasing less like a negotiation marathon and more like a sprint.Chapters00:00 – Meet Lindsey BardenA 20-year tenant rep veteran shares her journey from Virginia brokerage to founding Dark Horse CRE in East Tennessee.08:15 – Why East Tennessee Is So CompetitiveLindsey breaks down Knoxville's low vacancy,...

Thanks to our Partners, NAPA TRACS, Today's Class, KUKUI, and Pit Crew Loyalty Watch Full Video Episode Reaching 250,000 miles on a vehicle isn't luck—it's leadership. In this episode, we explore what long-term vehicle maintenance really looks like and why today's shops must rethink how they communicate with customers. Too often, maintenance is treated as a series of isolated repairs. This conversation reframes it as a strategic process built on education, transparency, planning, and advocacy. In this episode, you'll discover how to: Shift your shop culture from reactive repairs to proactive planningPosition service advisors as educators and advocatesUse cost-per-mile analysis to demonstrate real vehicle valueBuild trust through professional language and clear expectationsAlign inspections with long-term ownership goalsImprove maintenance acceptance without fear-based sellingCreate systems that support consistent follow-up Key Discussion Topics Why 250,000-mile vehicles are built through strategy, not chanceThe difference between transactional service and advisory leadershipUsing documentation and trends to guide decisionsStructuring pay plans to reinforce professionalismTurning maintenance into a long-term relationship Why This Episode Matters When customers understand that their vehicle can realistically reach 250,000 miles with the right care, everything changes. Trust improves. Approvals become easier. Loyalty deepens. And your shop evolves from a repair facility into a long-term partner in vehicle ownership. This episode shows how sophisticated professionalism, consistent processes, and education-first communication can transform both customer relationships and business performance. Brett Beachler, Beachler's Vehicle Care & Repair, Peoria, IL. Listen to Brett's previous episodes HERE Rena Rennebohm, CEO and Creator of Empowered Advisor. Rena's previous episodes 

In March 2022, Dr. Joseph Fraiman taped an internal call between FDA directors and physicians who were concerned about mRNA side effects in their patients – including the cardiac arrest and sudden death of a 7-year-old days after being injected with Pfizer's mRNA vaccine. “This was a top level meeting of directors,” Dr. Fraiman revealed to Ask Dr. Drew in Sept 2023. “This entire meeting terrified my entire work group.” The call – legally recorded by Dr. Fraiman – included FDA Director Dr. Peter Marks, Dr. Peter Doshi, Dr. Celia Witten, Dr. Sarah Walinsky, Dr. Lorrie McNeill, and many other experts. “What they're saying here is they're not doing statistical testing on adverse events. This is really insane to me,” Dr. Fraiman continued. “You know there's a problem if the vaccine group has a higher rate of them.” Dr. Joseph Fraiman, MD is an emergency physician and clinical researcher focused on harm-benefit analysis. He served as Medical Manager of Louisiana's Urban Search Rescue Disaster Task Force 1 and is lead author of a widely known re-analysis of mRNA vaccine serious harms. Follow at https://x.com/josephfraiman Dr. Stephanie Venn-Watson is Co-CEO and Co-Founder of Seraphina Therapeutics. She is a veterinary epidemiologist and author of “The Longevity Nutrient” (March 2025). Her background includes DARPA, the U.S. Navy Marine Mammal Program, and research on nutritional C15:0 deficiencies. Learn more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 • AUGUSTA PRECIOUS METALS – Thousands of Americans are moving portions of their retirement into physical gold & silver. Learn more in this 3-minute report from our friends at Augusta Precious Metals: ⁠⁠⁠⁠https://drdrew.com/gold⁠⁠⁠⁠ or text DREW to 35052 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer & Booking • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices